This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Primary coenzyme Q10 deficiency panel [13 genes]
Mitochondrial diseases are, as a group, the most common inherited metabolic disorders and the most frequent inherited disorders at the neurological level.
They are clinically heterogeneous, can occur at any age, and usually can produce a wide range of clinical symptoms, being often considered multisystem diseases. Some mitochondrial diseases can be grouped into specific syndromes, such as Leigh syndrome (infantile subacute necrotizing encephalomyopathy), MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), or Alpers-Huttenlocher syndrome. In addition to biochemical and histochemical analysis of tissue biopsy samples, diagnosis is usually based on clinical criteria. Not only does genetic testing contribute to better clinical and molecular characterization of these patients, it also helps provide appropriate genetic counseling for the individual and their family.
The prevalence of mitochondrial diseases that begin in childhood is between 5-15 per 100,000 individuals (Gorman et al., 2014). The most common presentation is Leigh syndrome (2.5 per 100,000 individuals). An estimated prevalence in adults is 9.6 per 100,000 (due to mtDNA mutations) and 2.9 per 100,000 individuals (caused by mutations in nuclear genes).
Mitochondrial defects can result from mutations in nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) genes. With regard to genetic suspicion, it is worth mentioning that 80% of adult-onset mitochondrial diseases are due to pathogenic variants in mtDNA; however, they only account for 20-25% of childhood-onset cases, where nuclear genes are more important (Gorman et al., 2014).
Steps to follow
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Mon–Thur: 8am – 5pm
5. Result: the report
Via: Client Site HIC / Client Site Imegen / Certified email
Solicita información de
Primary coenzyme Q10 deficiency panel
Turnaround time (TAT): 6 weeks
Ref. S-202008539
- APTX
- COQ2
- COQ4
- COQ5
- COQ6
- COQ7
- COQ8A
- COQ8B
- COQ9
- ETFDH
- FDX2
- PDSS1
- PDSS2
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.
- Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM. Mitochondrial diseases. Nat Rev Dis Primers. 2016 Oct 20;2:16080.